Recent Updates
Recently added Catalysts
ANIK Negative Sentiment Score: 20/100

ANIKA ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Anika Therapeutics, Inc. is currently under investigation by Bragar Eagel & Squire, P.C. on behalf of stockholders, focusing on potential violations of federal securities laws. The investigation was prompted by disappointing topline results from a pivotal clinical trial of Hyalofast, which failed to meet its pre-specified co-primary endpoints. Following this announcement, Anika's stock experienced a significant decline of 27.42%. The trial's complications, such as a high dropout rate and missed visits, may have contributed to the unfavorable outcomes.

Market Sentiment Analysis

CONCERNS & RISKS

  • Anika Therapeutics is under investigation for potential violations of federal securities laws.
  • The company’s stock price fell 27.42% following the announcement of disappointing clinical trial results.
  • The pivotal trial did not meet its co-primary endpoints, raising concerns about the product's efficacy.
  • A high dropout rate in the trial may have influenced the negative results.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options
If you purchased or acquired stock in Anika and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ: ANIK) on behalf of Anika stockholders. Our investigation concerns whether Anika has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On July 30, 2025, Anika issued a press release "announc[ing] topline results from its U.S. pivotal clinical trial of Hyalofast, a resorbable, hyaluronic acid scaffold used in conjunction with autologous bone marrow aspirate concentrate (BMAC) for cartilage repair." The press release stated that "[w]hile Hyalofast demonstrated consistent improvements in treated patients across all measures of pain and function relative to microfracture, the study did not meet its pre-specified co-primary endpoints. The study was likely impacted by both a higher subject dropout rate in the microfracture arm and missed visits during COVID. This resulted in missing data, which reduced the evaluable sample size and complicated the statistical analysis."
On this news, Anika's stock price fell $3.06 per share, or 27.42%, to close at $8.10 per share on July 30, 2025.
If you purchased or otherwise acquired Anika shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

Who should contact Bragar Eagel & Squire regarding Anika?

Investors who purchased Anika stock and suffered losses should contact them.

What caused Anika's stock price to fall?

The stock price fell after Anika reported that its clinical study did not meet its endpoints.

What is Hyalofast used for?

Hyalofast is a scaffold used for cartilage repair with autologous bone marrow concentrate.

How can investors reach Brandon Walker?

Investors can call Brandon Walker at (212) 355-4648 or email investigations@bespc.com.

Is there a cost to discuss legal options for Anika losses?

No, there is no cost or obligation for investors to discuss their legal options.

Last updated: Aug 26, 2025